Press Releases

 
Press Releases
Date Title and Summary View
Dec 19, 2014 SALT LAKE CITY, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca's drug Lynparza™ (olaparib). Lynparza is the first poly ADP-ribose...
Dec 9, 2014 Myriad myRisk™ Hereditary Cancer Test Finds 105 Percent More MutationsMyriad myChoice™ HRD Predicted Platinum Response in Early TNBCBRACAnalysis®Predicted Platinum Response in Metastatic TNBC SALT LAKE CITY, Dec. 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results from a new study that demons...
Dec 3, 2014 SALT LAKE CITY, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the presentation of eight new studies evaluating the use of its molecular and companion diagnostics in patients with breast cancer at the 2014 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, Dec. 9-13. Several studies will feature...
Dec 2, 2014 SALT LAKE CITY, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology (SUO) Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could sa...
Nov 20, 2014 BARCELONA, Spain, Nov. 20, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) and Myriad Genetics (Nasdaq:MYGN) today announced a collaboration utilizing Myriad's myChoice HRD companion diagnostic (CDx) to identify tumor tissue with a deficiency in homologous recombination. Under the terms of the agreement, TESARO will utilize Myriad's test to enr...
Nov 19, 2014 SALT LAKE CITY, Nov. 19, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today presented new data that showed Vectra® DA is a better predictor of radiographic progression over two years than other tests used to assess risk of joint damage in rheumatoid arthritis (RA), such as C-r...
Nov 10, 2014 SALT LAKE CITY, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that new data on Vectra® DA will be featured at the 2014 American College of Rheumatology (ACR) Annual Meeting, Nov. 15-19, 2014, in Boston, Massachusetts. "Vectra DA is a game changer fo...
Nov 7, 2014 SALT LAKE CITY, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented results from a prospective clinical utility study of its Myriad myPath Melanoma test at the 2014 American Society of Dermatopathology (ASDP) annual meeting in Chicago, Ill. Myriad myPath Melanoma is a genetic test that differentiates malignant melan...
Nov 4, 2014 Revenue of $168.8 million; diluted EPS of $0.21; adjusted EPS of $0.25myRisk Hereditary Cancer revenue of $53.1 million, up 95 percent sequentiallyDraft Medicare decision covering Prolaris for low-risk prostate cancer patientsCHMP recommends approval of olaparib in ovarian cancer patients with BRCA mutationsCompany reiterates fiscal year 2015 finan...
Nov 3, 2014 SALT LAKE CITY, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc. (NYSE:ABBV), a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a companion diagnostic in support of AbbVie's novel poly (ADP-ribose) pol...
Page:
1
... NextLast
= add release to Briefcase